Skip to main content
Halal FriendlyTakaful direct billing
EN/中文/BM
YILV CHINA logoYILV CHINA
★
boltLeading-Edge Clinical Care · Filling Malaysia's Treatment Gapslocal_hospitalGreen Channel at National Medical CentresHalal Friendly Medical Support

Frontier Technologies and Major Diseases in China

Breaking through the ceiling of conventional local treatment: commercial CAR-T cell immunotherapy, Bragg Peak proton and heavy-ion precision radiotherapy, extreme brainstem micro-neurosurgery and frontier targeted novel drugs (ADC). YILV CHINA builds a direct two-way specialist channel, so Malaysian patients with refractory critical illness do not lose the optimal treatment window to a long wait.

assignment_addFree Pre-Screening: Match a Specialty Department in ChinachatDirect WhatsApp Line to Our Kuala Lumpur Medical Officer
categoryClinical Fields
4 Core FieldsPrecisely covering unmet critical illness needs in Malaysia
medicationClinical Breakthroughs
30+ FrontierReserve of globally leading targeted drugs and cell therapies
speedResponse Time
24-48 hoursInitial routing plan reviewed by Grade 3A director-level specialists
apartmentDirect Authority Access
100% National LevelDirect access to top Grade 3A clinical centres in Beijing, Shanghai and Guangzhou
Clinical Excellences

In-Depth Analysis of China's Four Flagship Frontier Medical Technologies

An objective comparison of the current treatment landscape in Malaysia, breakthrough mechanisms at Chinese Grade 3A hospitals, the corresponding national medical centres and patient assessment criteria.

infoData updated to Q4 2024 NMPA (National Medical Products Administration) approval records
CAR-T cell therapy
Track 1 · Cell ImmunotherapyOvercoming Resistance

CAR-T Cell Immunotherapy

A revolutionary clearance therapy for haematological malignancies, using the patient's own engineered T cells for precise tumour killing.

Core IndicationsRelapsed/refractory diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), acute lymphoblastic leukaemia (B-ALL)
Indicative Cost (vs. Europe and the US)From approx. RM 640,000 (about one quarter of the cost in Europe, the US and Singapore)
check_circleClinical Advantages of Chinese Grade 3A Hospitals

China has the largest number of registered CAR-T clinical pipelines in the world. Commercial targets include not only the standard CD19 and BCMA; its dual-target constructs (such as combined CD19/CD22) and fully humanised engineering are global leaders, and the cell manufacturing cycle has been shortened to 9-14 days.

Corresponding National Medical Centres:
Institute of Hematology and Blood Diseases Hospital, CAMS (Tianjin)Ruijin Hospital, Shanghai Jiao Tong University School of MedicineBeijing Boren Hospital
Eligibility: ECOG score ≤2 · Resistance to second-line or later chemotherapyRequest CAR-T Pre-Screening
Proton and heavy ion therapy
Track 2 · Precision Radiotherapy for Solid TumoursZero Excess Radiation

Proton and Heavy-Ion Precision Radiotherapy

The "stereotactic demolition" of tumour treatment, using the Bragg Peak to release maximum energy within millimetres while protecting adjacent vital organs.

Core IndicationsSkull base chordoma, locally recurrent nasopharyngeal carcinoma, unresectable pancreatic/liver cancer, paediatric brain tumours
Offsetting the Malaysian Treatment BottleneckMalaysia has no commercial proton facility, and treatment in China means no six-month wait
check_circleThe Physical Advantage of the Bragg Peak

Conventional photon radiotherapy penetrates the whole body and causes severe damage to tissue behind the target. Heavy-ion beams release only a low dose until they reach tumour depth, then instantly deposit their peak energy to destroy both DNA strands of the tumour cell, with the dose falling to zero behind the target, greatly reducing oral mucosal injury, brain damage and the risk of secondary tumours.

Corresponding National Medical Centres:
Shanghai Proton and Heavy Ion Center (SPHIC)Shandong Cancer Hospital Proton Clinical Research CentreHebei Yizhou Cancer Hospital (Paediatric Radiotherapy Centre)
Assessment Note: Contrast-enhanced MRI/PET-CT imaging from the last 3 months requiredSubmit Imaging for a Radiotherapy Feasibility Review
Complex Neurosurgery
Track 3 · Complex NeurosurgeryOperating in the Surgical No-Go Zone

Complex Brain Tumours and Micro-Neurosurgery

Pushing surgical limits in the brainstem, skull base and eloquent areas that govern the "seat of life", achieving total tumour resection while maximally preserving neurological function.

Core IndicationsBrainstem glioma/cavernous haemangioma, acoustic neuroma (with facial and cochlear nerve preservation), complex craniopharyngioma
Malaysia-China Coordinated SupportTwo-way consultation to determine fitness to fly and transfer indications
check_circleIntraoperative Neuronavigation Linked with Multimodal Imaging

China's leading neurosurgery teams perform tens of thousands of operations each year and are equipped with high-field intraoperative iMRI, intraoperative CT and a full set of continuous intraoperative neurophysiological monitors. Under the microscope they distinguish tumour from cranial nerve fascicles at millimetre resolution, achieving facial nerve preservation in more than 90% of acoustic neuroma cases.

Corresponding National Medical Centres:
Beijing Tiantan Hospital, Capital Medical University (National Centre for Neurological Disorders)Huashan Hospital, Fudan University (Neurosurgery)
Key Requirements: Stable vital signs · Original DICOM thin-slice scan discSubmit to Tiantan / Huashan Specialists for Review
Rare mutations and ADC
Track 4 · Novel Targeted Drugs and ADCEarlier Access to New Drugs

Rare Gene Mutations and Frontier Antibody-Drug Conjugates

Addressing chemotherapy resistance in advanced tumours and the shortage of targeted drugs in Malaysia, with direct access to China's leading channels for newly approved medicines.

Core IndicationsEGFR 20ins, KRAS G12C, HER2-mutant resistant solid tumours, Claudin 18.2 gastric/pancreatic cancer
China's Faster Drug Approval TimelineGreen channel for new drug review; some frontier ADCs are approved 1-2 years earlier than in ASEAN
check_circle"Precision Guidance" of Molecular Targeting and Enrolment in Global Clinical Research

China is a global hub for ADC development, with a steady stream of innovative drugs against frontier targets such as Claudin 18.2, TROP-2 and HER3. For patients with advanced lung or gastrointestinal cancer who have become resistant to multiple lines of treatment in Malaysia, coming to China offers access not only to marketed new drugs, but also, through compassionate-use (IIT) channels, a lawful route to hope.

Corresponding National Medical Centres:
Cancer Hospital, Chinese Academy of Medical Sciences (Beijing)Sun Yat-sen University Cancer Center (Guangzhou)Fudan University Shanghai Cancer Center (Shanghai)
Report Requirements: Local Malaysian NGS sequencing and pathology tissue slide loans acceptedMatch a Frontier Targeted Regimen
Patient Decision Guide

When should you decisively consider new therapies in China?

Cross-border treatment is a serious family medical decision. When local care in Malaysia runs into the key bottlenecks below, initiating an authoritative second opinion from China is often the best moment to seize the initiative.

medication_liquid

Resistance to the Local Regimen

After second-line chemotherapy or radiotherapy at a Malaysian public hospital (such as HKL) or a private specialist hospital, the tumour progresses; the attending doctor states clearly that there is "no other standard first-line guideline regimen" and recommends palliative care only.

arrow_forwardMatches CAR-T / frontier ADC drugs
strikethrough_s

Target Identified but No Drug Locally

A local NGS report shows a specific targetable mutation (such as KRAS G12C or a rare HER2 mutation), but the drug is not approved in Malaysia, or self-payment is prohibitively expensive with a high risk of supply interruption.

arrow_forwardCommercially available and NMPA-approved in China
warning

Risky Location Deemed Unresectable

The tumour lies against "forbidden" zones such as the brainstem, optic chiasm or aorta; local doctors assess the risk of surgical disability or death as very high and rule out conventional resection, so a higher-order minimally invasive or precision approach is needed.

arrow_forwardTiantan/Huashan neurosurgery and proton/heavy-ion therapy
airline_stops

Fitness Still Allows Travel

The patient's performance status is ECOG 0-2 (able to manage daily living and out of bed for more than half the day), with no cachexia or multiple organ failure, and the patient is fit for a 4-6 hour direct flight to Beijing, Shanghai or Guangzhou.

arrow_forwardSeamless wheelchair escort from airport to ward
Clinical Routing

From Kuala Lumpur to a Ward in China: The Full Treatment Journey for Malaysian Patients

Professional medical record translation · Two-way specialist review · Dedicated green channel admission

01

Collecting Malaysian Records

The patient submits English pathology reports, DICOM imaging discs and discharge summaries from the Malaysian hospital; our officer collects them in person or receives them online.

Reviewed directly at our KL office
02

Bilingual Medical Standardisation

A medical translation team with clinical backgrounds converts English records into the standard Chinese clinical course summary accepted by Chinese Grade 3A hospitals.

Issued within 24 hours
03

Grade 3A Director Review

Records go directly to the lead specialists at national medical centres to assess whether admission offers a clear benefit and to estimate the treatment duration and cost.

Precisely matched to the right department
04

China Entry and Exit Coordination

We issue the official medical invitation letter, assist with visa-free entry or an expedited S2 medical companion visa, and reserve a ward bed.

Official documentation direct from the hospital
05

Full Escort on Arrival in China

Private airport pick-up, direct admission to the matched ward, bilingual escorts in China to assist with tests and specialist consultations, and customised Halal meals.

Seamless, closed-loop personal care
Clarifications

Frequently Asked Questions on Diseases and Treatment in China

Answers to the real concerns of Malaysian patients and families about technology, language, visas and medical record transfer.

lockPDPA Medical-Grade Encrypted Security

Submit your medical records
for free initial routing advice from Chinese Grade 3A hospitals

There is no need to fly to China first. A licensed medical officer in Kuala Lumpur performs the initial review and, within as little as 24 hours, reports whether the patient meets the clinical admission criteria for CAR-T / proton and heavy-ion therapy / frontier targeted drugs.

verifiedNo layered mark-ups from overseas agencies · Medical fees paid directly to the public hospital
scheduleOur specialist panel issues a referral feasibility opinion within 24-48 hours
phone_in_talkHotline / WhatsApp: +60 19-3314778
Upload Malaysian Medical Reports (optional; you may also send them later via WhatsApp)
upload_fileClick to select files (PDF, JPG, DICOM, max 50MB)English-language Malaysian discharge summaries, PET-CT reports or gene sequencing files are supported
After submission, a Kuala Lumpur medical adviser will contact you by phone or WhatsApp within 4 hours to confirm the details of your medical history.